KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $1.2 billion.

  • Alnylam Pharmaceuticals' Total Current Liabilities rose 27.43% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 27.43%. This contributed to the annual value of $1.2 billion for FY2024, which is 22.58% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Total Current Liabilities is $1.2 billion, which was up 22.58% from $967.8 million recorded in FY2023.
  • Alnylam Pharmaceuticals' Total Current Liabilities' 5-year high stood at $1.2 billion during FY2024, with a 5-year trough of $585.3 million in FY2020.
  • In the last 3 years, Alnylam Pharmaceuticals' Total Current Liabilities had a median value of $967.8 million in 2023 and averaged $974.0 million.
  • Data for Alnylam Pharmaceuticals' Total Current Liabilities shows a peak YoY spiked of 65.99% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Total Current Liabilities stood at $585.3 million in 2020, then grew by 18.87% to $695.7 million in 2021, then climbed by 10.38% to $767.9 million in 2022, then rose by 26.03% to $967.8 million in 2023, then climbed by 22.58% to $1.2 billion in 2024.